文献速递垂体与肾上腺疾病

原发性醛固酮增多症筛查与确诊试验中醛固酮LC-MS/MS检测的特异性阈值

Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

该研究比较了放射免疫法(RIA)与液相色谱-串联质谱法(LC-MS/MS)测定醛固酮,并评估了LC-MS/MS专用切点在原发性醛固酮增多症(PA)筛查和确诊试验中的表现。结果显示LC-MS/MS测定的醛固酮较RIA低27.8%,提出的LC-MS/MS切点(FST 133 pmol/L,ARR 55 pmol/mU)与现行RIA切点诊断一致性良好。

要点

  • LC-MS/MS测定的醛固酮较RIA低约27.8%,需调整PA诊断切点。
  • 提出的FST切点133 pmol/L与现行RIA切点165 pmol/L诊断一致性良好(κ=0.736)。
  • 提出的ARR切点55 pmol/mU与现行RIA切点70 pmol/mU在筛查敏感性或特异性上无差异。

核心结论

  • 若采用LC-MS/MS测定醛固酮,需调整现行PA诊断切点;初步结果显示提出的LC-MS/MS切点性能与现行RIA切点相当。

主要发现

  • 164对FST样本中,血清PACLC-MS/MS中位数较血浆PACRIA低27.8%(P < 0.05)。
  • 两种检测法呈正相关(Spearman系数0.894,P < 0.01;Pearson r系数0.861,P < 0.01)。
  • 37例患者FST诊断一致(29例阳性,8例阴性),4例诊断不一致。
  • 现行FST诊断切点PACRIA 165 pmol/L与提出的PACLC-MS/MS切点133 pmol/L之间一致性良好(κ系数0.736,P < 0.01)。
  • 37例FST结果一致的患者中,现行ARR切点70 pmol/mU(PACRIA/DRC)与提出的切点55 pmol/mU(PACLC-MS/MS/DRC)筛查PA的敏感性(89.7% vs 93.1%)或特异性(87.5% vs 87.5%)无差异。

关键数值与推荐

  • FST确诊切点:PACRIA 165 pmol/L对应提出的PACLC-MS/MS 133 pmol/L。
  • ARR筛查切点:PACRIA/DRC 70 pmol/mU对应提出的PACLC-MS/MS/DRC 55 pmol/mU。
  • LC-MS/MS测定的醛固酮较RIA低27.8%(中位数)。

临床怎么用

  • 采用LC-MS/MS测定醛固酮时,应使用其特异性切点(如FST 133 pmol/L、ARR 55 pmol/mU)进行PA筛查和确诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Current threshold values for primary aldosteronism (PA) diagnostic testing are based on measuring aldosterone (PAC) using immunoassays. Quantification of PAC by liquid chromatography-tandem mass spectrometry (LC-MS/MS) yields lower values. OBJECTIVE: To compare aldosterone measurement by radioimmunoassay (RIA) with LC-MS/MS and evaluate performances of proposed LC-MS/MS-specific cutoffs for PA screening and confirmatory testing. PATIENTS AND INTERVENTION: Forty-one patients underwent aldosterone/renin ratio (ARR) testing to screen for, and fludrocortisone suppression testing (FST) to confirm or exclude, PA. Renin (DRC) was measured by chemiluminescent immunoassay. RESULTS: Median serum PACLC-MS/MS was 27.8% lower (P < 0.05) than plasma PACRIA in 164 pairs of FST samples. A positive correlation (Spearman coefficient, 0.894, P < 0.01; Pearson r coefficient, 0.861, P < 0.01) was observed between the two assays. Thirty-seven patients showed consistent FST diagnoses (29 positive, 8 negative), whereas four showed inconsistent FSTs by the two assays. Good agreement (κ coefficient, 0.736; P < 0.01) was observed between the current FST diagnostic PACRIA cutoff of 165 pmol/L and the proposed PACLC-MS/MS cutoff of 133 pmol/L. Among 37 patients with consistent FST results, no differences were observed in sensitivity (89.7% vs 93.1%) or specificity (87.5% vs 87.5%) for PA screening between the current ARR cutoff of 70 pmol/mU (PACRIA/DRC) and the proposed cutoff of 55 pmol/mU (PACLC-MS/MS/DRC). CONCLUSIONS: Adjustment of the current cutoffs for PA diagnostic testing is necessary if PAC is measured by LC-MS/MS. Our preliminary results suggest that the proposed LC-MS/MS cutoffs for ARR and FST perform as well as current RIA cutoffs.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Guo Z, Poglitsch M, McWhinney BC, et al. Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism. J Clin Endocrinol Metab. 2018. PMID: 30137438. doi:10.1210/jc.2018-01041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。